December 18, 2025

Primary Analysis Shows Survival Benefit With Bemarituzumab Plus Chemotherapy in Gastric or Gastroesophageal Junction Cancer

The addition of bemarituzumab, a first-in-class anti-FGFR2b antibody, to mFOLFOX6 chemotherapy significantly improved overall survival in patients with FGFR2b-overexpressing (≥ 10% tumor cell staining...

The ASCO Post

December 18, 2025

FDA Approves Durvalumab With FLOT for Resectable Gastric/GEJ Adenocarcinoma

On November 25, 2025, the U.S. Food and Drug Administration (FDA) approved durvalumab (Imfinzi) in combination with fluorouracil, leucovorin, oxaliplatin, and docetaxel (FLOT) chemotherapy as neoadjuv...

The ASCO Post

December 09, 2025

Study Identifies Rectal Bleeding as Key Predictor of Early-Onset Colorectal Cancer

In individuals younger than age 50 undergoing a colonoscopy, greater odds for having colorectal cancer were observed among those who presented with rectal bleeding, according to findings from a study ...

The ASCO Post

December 09, 2025

Validation of Pathology-AI Integration Tool for Risk Stratification in Locally Advanced Colon Cancer Without Chemotherapy

The Combined Analysis of Pathology and Artificial Intelligence (AI; CAPAI) model effectively stratified patients with colon cancer into distinct prognostic groups, identifying nearly half as low-risk,...

The ASCO Post

December 05, 2025

Final Overall Survival Confirms Benefit of Durvalumab Plus FLOT in Resectable Gastric and Gastroesophageal Junction Adenocarcinomas

The addition of the PD-L1–targeting monoclonal antibody durvalumab to conventional perioperative chemotherapy with fluorouracil, leucovorin, oxaliplatin, and docetaxel (FLOT) resulted in a statistical...

The ASCO Post

December 01, 2025

Reaching Everyone, Everywhere: Breaking Barriers in Hepatitis C Testing

As global funding declines, decentralized testing, telehealth, and community-based care are helping expand access to HCV diagnosis and treatment

The Pathologist

December 01, 2025

WHO Issues Conditional GLP-1 Obesity Guideline

New recommendations emphasize equity barriers, health-system readiness, and the need for integrated chronic-disease management.

Conexiant

November 25, 2025

AGA unveils new clinical practice guideline for Crohn's disease

Of the 16 recommendations, the panel rated one as “strong,” nine as “conditional,” and six as “knowledge gaps.”

Conexiant

November 13, 2025

Final Overall Survival Confirms Benefit of Durvalumab Plus FLOT in Resectable Gastric and Gastroesophageal Junction Adenocarcinomas

The addition of the PD-L1–targeting monoclonal antibody durvalumab to conventional perioperative chemotherapy with fluorouracil, leucovorin, oxaliplatin, and docetaxel (FLOT) resulted in a statistical...

The ASCO Post